Exogenous expression of hRFI induces multidrug resistance through escape from apoptosis in colorectal cancer cells

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2737-2742

  Konishi, Tsuyoshi ^a   Sasaki, Shin ^a   Watanabe, Toshiaki ^a   Kitayama, Joji ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

5 Fluorouracil; Apoptosis; Chemotherapy; Cisplatin; Colorectal cancer; hRFI; Irinotecan

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; CISPLATIN; FLUOROURACIL; INHIBITOR OF APOPTOSIS PROTEIN; IRINOTECAN; PROTEIN HUMAN RING FINGER 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

APOPTOSIS; CAMPTOTHECIN; CARRIER PROTEINS; CASPASE 3; CASPASES; CELL GROWTH PROCESSES; CISPLATIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FLUOROURACIL; HCT116 CELLS; HUMANS; TRANSFECTION;

EID: 22944442607     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sasaki S, Nakamura T, Arakawa H, Mori M, Watanabe T, Nagawa H and Croce CM: Isolation and characterization of a novel gene, hRFI, preferentially expressed in esophageal cancer. Oncogene 21: 5024-5030, 2002.
2. Syken J, De-Medina T and Munger K: TID1, a human homolog of the Drosophila tumor suppressor 1(2)tid, encodes two mitochondrial modulators of apoptosis with opposing functions. Proc Natl Acad Sci USA 96: 8499-8504, 1999.
3. Holcik M, Gibson H and Korneluk RG: XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6: 253-261, 2001.
4. Sasaki S, Watanabe T, Konishi T, Kitayama J and Nagawa H: Effects of expression of hRFI on adenoma formation and tumor progression in colorectal adenoma-carcinoma sequence. J Exp Clin Cancer Res 23: 507-512, 2004.
5. Sasaki S, Kitayama J, Watanabe T, Konishi T and Nagawa H: Diffuse expression of hRFI is correlated with blood vessel invasion in gastric carcinoma. Jpn J Clin Oncol 34: 584-587, 2004.
6. Crul M, van Waardenburg RC, Beijnen JH and Schellens JH: DNA-based drug interactions of cisplatin. Cancer Treat Rev 28: 291-303, 2002.
7. Li LH, Fraser TJ, Olin EJ and Bhuyan BK: Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643-2650, 1972.
8. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
9. Konishi T, Sasaki S, Watanabe T, Kitayama J and Nagawa H: Overexpression of hRFI (human ring finger homologous to inhibitor of apoptosis protein type) inhibits death receptor-mediated apoptosis in colorectal cancer cells. Mol Cancer Ther 4: 743-750, 2005.
10. Krammer PH: CD95's deadly mission in the immune system. Nature 407: 789-795, 2000.
11. Roy S and Nicholson DW: Cross-talk in cell death signaling. J Exp Med 192: 21-26, 2000.
12. Suzuki Y, Nakabayashi Y and Takahashi R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 98: 8662-8667, 2001.
13. MacFarlane M, Merrison W, Bratton SB and Cohen GM: Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277: 36611-36616, 2002.
14. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T and Muto T: 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 78: 986-992, 1998.
15. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T and Tanigawa N: Expression of survivin correlates with apoptosis, proliferation and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032, 2001.
16. Mesri M, Wall NR, Li J, Kim RW and Altieri DC: Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108: 981-990, 2001.